Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

日水製薬は6月1日、C.difficile（クロストリジウム・ディフィシル） ※1 の毒素を検出する簡易検査キット「TOX A/B QUIK CHEK」を発売した。このキットは、C.difficileが産生する毒素のうちトキシンAとトキシンBの2種類を検出できるのが特徴で、従来のトキシン ...

In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

The pharmacologists and toxicologists Prof. Dr. Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the University of Freiburg have identified the molecular docking site that is responsible for ...

Newly published research by investigators at the Children’s Hospital of Philadelphia (CHOP) has started to answer the question of why nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbate ...

Clostridium difficile is an unpleasant, sometimes severe, and potentially lethal infection. It is an enteric pathogen whose armory involves the production of a toxin leading to gut dysphoria and ...

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...